Search

Displaying results 6031 - 6040 of 10000 in total
  1. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  2. Drug

    RS5441

    go.drugbank.com/drugs/DB33178
    Experimental

    RS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]

  3. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  4. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

  5. Drug

    Filaminast

    go.drugbank.com/drugs/DB02660
    Experimental

    Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  6. Drug

    AGS-16C3F

    go.drugbank.com/drugs/DB17551
    Investigational

    AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. … AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).

  7. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919] … EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.

  8. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  9. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). … OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis.

    Synonyms: Combretastatin A1 diphosphate, Combretastatin A-1 bis(phosphate)
  10. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).